Hong Kong Stocks Movement | BIOCYTOGEN-B (02315) Surges Over 5% in Morning Trading on Strong Interim Results, Gene Editing Technology Value Highlighted

Stock News
Sep 03

BIOCYTOGEN-B (02315) surged over 5% in morning trading. As of press time, the stock was up 4.83% to HK$24.76, with turnover of HK$7.44 million.

On the news front, BIOCYTOGEN-B recently released its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 621 million, representing a 51.3% year-on-year increase. Profit attributable to shareholders reached RMB 47.999 million, turning from loss to profit compared to the same period last year. Earnings per share stood at RMB 0.12.

In the first half of 2025, the company's preclinical products and services business, centered on innovative animal model sales, achieved operating revenue of RMB 458 million, up 56.9% from the same period last year, while maintaining a high gross margin of approximately 70%. As another core driver of the company's performance growth, the antibody discovery business generated operating revenue of RMB 163 million in the first half of 2025, up 37.8% year-on-year, with a gross margin of approximately 90%.

Built on globally leading gene editing technology, BIOCYTOGEN has successfully established a dual-engine growth model centered on innovative animal models and antibody molecule licensing and development, creating a distinctive platform-based innovative biotech path that differs from traditional CROs and pharmaceutical companies.

Notably, leveraging its RenMice series fully human antibody mouse platform, the "Thousand Mice, Ten Thousand Antibodies" program, and a global patent network, the company has gradually built dual moats in technology and patents, forming competitive barriers that are difficult to replicate. As BIOCYTOGEN accelerates in establishing its industry position as a "global new drug origin," its long-term growth value and investment attractiveness continue to enhance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10